Veraxa Biotech (NASDAQ:VRXA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Veraxa Biotech (NASDAQ:VRXA) from a sell rating to a hold rating in a research note published on Monday morning,Wall Street Zen reports.

Veraxa Biotech Trading Down 1.4%

Shares of Veraxa Biotech stock opened at $1.38 on Monday. Veraxa Biotech has a 1 year low of $1.27 and a 1 year high of $27.36.

Insider Activity at Veraxa Biotech

In other news, Director Oliver Rolf Baumann bought 50,000 shares of the business’s stock in a transaction dated Thursday, August 27th. The stock was purchased at an average cost of $1.50 per share, with a total value of $75,000.00. Following the acquisition, the director directly owned 5,773,618 shares in the company, valued at $8,660,427. This trade represents a 0.87% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Veraxa Biotech Company Profile

Veraxa Biotech AG is a biotechnology company focused on developing targeted antibody-based medicines, with an emphasis on antibody-drug conjugates (ADCs). These therapies are designed to use antibodies to identify specific cells and deliver therapeutic agents more selectively.

The company’s work includes antibody discovery, therapeutic development and the design of ADC candidates that combine targeting antibodies with drug payloads. Its research is directed primarily toward potential treatments for cancer and other serious diseases, although specific development programs and product approvals may change as its pipeline advances.

Publicly available information about Veraxa Biotech’s corporate history, geographic operations and leadership is limited.